000302329 001__ 302329
000302329 005__ 20250630113838.0
000302329 0247_ $$2doi$$a10.3390/ph18060906
000302329 0247_ $$2pmid$$apmid:40573302
000302329 037__ $$aDKFZ-2025-01324
000302329 041__ $$aEnglish
000302329 082__ $$a610
000302329 1001_ $$0P:(DE-He78)cf082215dd3b3a42943d2dfe2e22ec20$$aHennrich, Ute$$b0$$eFirst author$$udkfz
000302329 245__ $$aRevolutionizing Prostate Cancer Detection: The Role of Approved PSMA-PET Imaging Agents.
000302329 260__ $$aBasel$$bMDPI$$c2025
000302329 3367_ $$2DRIVER$$aarticle
000302329 3367_ $$2DataCite$$aOutput Types/Journal article
000302329 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1751273323_21306$$xReview Article
000302329 3367_ $$2BibTeX$$aARTICLE
000302329 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000302329 3367_ $$00$$2EndNote$$aJournal Article
000302329 500__ $$a#EA:W630#LA:E270#
000302329 520__ $$aLocametz®/Illuccix®/GozellixTM (Novartis AG (Basel, Switzerland) and Telix Pharmaceuticals, Ltd. (Melbourne, Australia), all three [68Ga]Ga-PSMA-11), Pylarify®/Pylclari® (Progenics Pharmaceuticals, Inc. (New York, USA) and Curium PET France SA (Paris, France), both [18F]DCFPyL), Radelumin® (ABX GmbH (Radeberg, Germany), [18F]PSMA-1007), and Posluma® (Blue Earth Diagnostics, Ltd. (Oxford, UK), [18F]rhPSMA-7.3) are four approved PSMA-PET imaging agents that have significantly advanced the diagnosis and management of prostate cancer. These agents offer a new level of precision and accuracy, enabling clinicians to detect prostate cancer with enhanced sensitivity. As a result, they play a critical role in improving detection, staging, and management, ultimately enhancing clinical outcomes for patients. Their use in routine clinical practice is expected to increase diagnostic precision and provide clearer pathways for personalized therapy. This review offers a comprehensive chemical, pharmaceutical, and medicinal overview, discusses comparative studies, and highlights additional highly relevant candidates for prostate cancer detection.
000302329 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000302329 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000302329 650_7 $$2Other$$aEMA approval
000302329 650_7 $$2Other$$aFDA approval
000302329 650_7 $$2Other$$aGozellixTM
000302329 650_7 $$2Other$$aIlluccix®
000302329 650_7 $$2Other$$aLocametz®
000302329 650_7 $$2Other$$aPET diagnostics
000302329 650_7 $$2Other$$aPSMA
000302329 650_7 $$2Other$$aPosluma®
000302329 650_7 $$2Other$$aPylarify®
000302329 650_7 $$2Other$$aPylclari®
000302329 650_7 $$2Other$$aRadelumin®
000302329 650_7 $$2Other$$afluorine-18
000302329 650_7 $$2Other$$agallium-68
000302329 650_7 $$2Other$$aprostate cancer
000302329 7001_ $$0P:(DE-He78)f4cac9f609a993052af693b0acbae449$$aWagner, Laurène$$b1$$udkfz
000302329 7001_ $$0P:(DE-He78)857dc4f13329fd151170f3e2b9edfba0$$aTas, Harun$$b2$$udkfz
000302329 7001_ $$0P:(DE-HGF)0$$aKovacs, Luciana$$b3
000302329 7001_ $$0P:(DE-He78)0f034e05cefb010f991ef8b96009d95c$$aBenesova-Schäfer, Martina$$b4$$eLast author$$udkfz
000302329 773__ $$0PERI:(DE-600)2193542-7$$a10.3390/ph18060906$$gVol. 18, no. 6, p. 906 -$$n6$$p906$$tPharmaceuticals$$v18$$x1424-8247$$y2025
000302329 909CO $$ooai:inrepo02.dkfz.de:302329$$pVDB
000302329 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)cf082215dd3b3a42943d2dfe2e22ec20$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000302329 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f4cac9f609a993052af693b0acbae449$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000302329 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)857dc4f13329fd151170f3e2b9edfba0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000302329 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000302329 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0f034e05cefb010f991ef8b96009d95c$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000302329 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000302329 9141_ $$y2025
000302329 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPHARMACEUTICALS-BASE : 2022$$d2024-12-28
000302329 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-28
000302329 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-28
000302329 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-04-10T15:30:02Z
000302329 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-04-10T15:30:02Z
000302329 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-04-10T15:30:02Z
000302329 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2024-04-10T15:30:02Z
000302329 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-28
000302329 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-28
000302329 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-28
000302329 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-28
000302329 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-28
000302329 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-28
000302329 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-28
000302329 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-28
000302329 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-28
000302329 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-28
000302329 9202_ $$0I:(DE-He78)E270-20160331$$kE270$$lTranslationale Radiotheranostik$$x0
000302329 9201_ $$0I:(DE-He78)W630-20160331$$kW630$$lRadiopharmazeutika und Präklinische Studien$$x0
000302329 9201_ $$0I:(DE-He78)E270-20160331$$kE270$$lTranslationale Radiotheranostik$$x1
000302329 9200_ $$0I:(DE-He78)W630-20160331$$kW630$$lRadiopharmazeutika und Präklinische Studien$$x0
000302329 980__ $$ajournal
000302329 980__ $$aVDB
000302329 980__ $$aI:(DE-He78)W630-20160331
000302329 980__ $$aI:(DE-He78)E270-20160331
000302329 980__ $$aUNRESTRICTED